FDA approves Retatrutide this year?

Resolution Criteria

Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form If the listed drug is approved within this market’s timeframe, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.

The prediction market on FDA approval of retatrutide before the end of 2026 is heavily skewed toward a 'No' outcome, with the 'Yes' position representing a small minority of market volume. Retatrutide, Eli Lilly's triple agonist drug under investigation for obesity and related conditions, has not yet completed the regulatory pathway required for FDA approval. Resolution is determined by an official FDA approval letter issued by 31 December 2026.

Market structure

This is a binary yes/no market with a single tracked outcome: whether the FDA issues a qualifying approval for retatrutide by 31 December 2026. Volume is heavily concentrated on the 'No' side, reflecting the early stage of the regulatory process. Resolution requires an official FDA approval letter for an NDA, BLA, or equivalent application. Emergency Use Authorisations, Complete Response Letters, and compassionate use programmes do not qualify. The primary resolution source is official FDA documentation.

Background

Retatrutide, also identified as LY3437943, is an investigational triple agonist developed by Eli Lilly that simultaneously targets GIP, GLP-1, and glucagon receptors. This mechanism distinguishes it from existing approved obesity drugs such as tirzepatide, which acts on two receptor types. Phase 2 trial results published in 2023 demonstrated substantial weight reduction in participants with obesity, prompting significant clinical and commercial interest. Eli Lilly has since progressed retatrutide into Phase 3 trials across multiple indications, including obesity, type-2 diabetes, metabolic dysfunction-associated steatohepatitis, and knee osteoarthritis. The drug sits within a rapidly expanding class of incretin-based therapies that has transformed the obesity and metabolic disease treatment landscape, drawing intense regulatory and investor scrutiny.

Key factors

The most significant structural factor is the status of Eli Lilly's Phase 3 programme. FDA approval requires completion of pivotal trials, compilation of a full regulatory submission, and review under standard or expedited pathways — a process that typically spans several years from Phase 3 initiation. If Eli Lilly submits an NDA or BLA and the FDA grants Priority Review, the standard review clock is six months; standard review runs twelve months. The FDA could also grant Breakthrough Therapy Designation, which accelerates development guidance but does not guarantee a shortened review timeline. Any safety signals emerging from ongoing Phase 3 studies could prompt the FDA to issue a Complete Response Letter, which does not qualify for resolution. Retatrutide is being studied across multiple indications simultaneously; approval of any single indication before 31 December 2026 would satisfy resolution criteria. Manufacturing readiness, labelling negotiations, and potential advisory committee scheduling represent additional procedural dependencies within the review window.

FAQ